Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Human complex I defects in neurodegenerative diseases

A H Schapira1

  • 1University Department of Clinical Neurosciences, Royal Free Hospital School of Medicine, Rowland Hill Street, London NW3 2PF, UK. schapira@rfhsm.ac.uk

Biochimica Et Biophysica Acta
|June 19, 1998
PubMed
Summary

Complex I deficiency is linked to neurodegenerative diseases like Parkinson's and Leber's hereditary optic neuropathy (LHON). While mitochondrial DNA mutations cause LHON, nuclear defects or toxins are implicated in dystonia and Parkinson's disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of ambroxol on the autophagy-lysosome pathway and mitochondria in primary cortical neurons.

Scientific reports·2018
Same author

Practical recommendations for the process of proposing, planning and writing a neurological management guideline by EAN task forces.

European journal of neurology·2015
Same author

The role of functional dopamine-transporter SPECT imaging in parkinsonian syndromes, part 2.

AJNR. American journal of neuroradiology·2014
Same author

The role of functional dopamine-transporter SPECT imaging in parkinsonian syndromes, part 1.

AJNR. American journal of neuroradiology·2014
Same author

Early L-dopa, but not pramipexole, restores basal ganglia activity in partially 6-OHDA-lesioned rats.

Neurobiology of disease·2013
Same author

Colloidal gold staining and immunodetection in 2-d protein mapping.

Methods in molecular biology (Clifton, N.J.)·2012

Area of Science:

  • Biochemistry
  • Neuroscience
  • Genetics

Background:

  • Complex I deficiency is implicated in various neurological disorders, including Parkinson's disease (PD), dystonia, and Leber's hereditary optic neuropathy (LHON).
  • This deficiency is detectable in blood for these conditions, but causative mutations have primarily been identified in mitochondrial DNA (mtDNA) for LHON.

Purpose of the Study:

  • To investigate the underlying causes of Complex I deficiency in neurodegenerative disorders.
  • To differentiate between mitochondrial DNA (mtDNA) and nuclear gene defects or environmental factors in the pathogenesis of these conditions.

Main Methods:

  • Analysis of Complex I deficiency in blood samples.
  • Utilizing rho degrees cybrid studies to assess the role of mtDNA.
  • Comparing findings in LHON, dystonia, and Parkinson's disease.

Related Experiment Videos

Main Results:

  • Specific mtDNA mutations identified as a cause for Complex I deficiency in a subgroup of LHON patients.
  • mtDNA appears to be the primary determinant in some Complex I deficiencies, as suggested by cybrid studies.
  • Nuclear gene defects or toxic influences, such as MPTP in PD, are more likely causes for Complex I deficiency in dystonia and Parkinson's disease.

Conclusions:

  • Complex I deficiency has diverse etiologies, involving both mtDNA and nuclear factors, depending on the specific neurodegenerative disorder.
  • Understanding these distinct pathways is crucial for unraveling the pathogenesis of neurodegeneration, particularly in PD.
  • Toxins like MPTP play a significant role in understanding neurodegenerative disease mechanisms.